AR055608A1 - Combinacion de un agente hipnotico y de r (+) - alfa-( 2,3- dimetoxi - fenil) -1- (2- (4-fluorofenil)etil]-4-piperidinmetanol y su aplicacion terapeutica - Google Patents

Combinacion de un agente hipnotico y de r (+) - alfa-( 2,3- dimetoxi - fenil) -1- (2- (4-fluorofenil)etil]-4-piperidinmetanol y su aplicacion terapeutica

Info

Publication number
AR055608A1
AR055608A1 ARP060103593A ARP060103593A AR055608A1 AR 055608 A1 AR055608 A1 AR 055608A1 AR P060103593 A ARP060103593 A AR P060103593A AR P060103593 A ARP060103593 A AR P060103593A AR 055608 A1 AR055608 A1 AR 055608A1
Authority
AR
Argentina
Prior art keywords
combination
fluorophenyl
ethyl
hypnotic
agent
Prior art date
Application number
ARP060103593A
Other languages
English (en)
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of AR055608A1 publication Critical patent/AR055608A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Combinacion de un agente hipnotico de accion a corto plazo y de R-(+)-alfa-(2,3-dimetoxifenil)-1-[2-(4-fluorofenil)etil]-4-piperidin-metanol (compuesto A) o su profármaco que presenta la formula (2) en la que R es alquilo C1-20, o una sal suya farmacéuticamente aceptable. La combinacion de la presente es util en el tratamiento de una variedad de trastornos del sueno. Reivindicacion 3: La combinacion establecida en la reivindicacion 1, en la que el agente hipnotico de accion a corto plazo es un modulador de receptores de GABA-A, benzodiacepina, un derivado de melatonina o un agonista de receptores de melatonina. Reivindicacion 4: La combinacion establecida en la reivindicacion 1, en la que el agente hipnotico de accion a corto plazo se selecciona del grupo que consiste en zolpidem, zopiclona, eszopiclona, zaleplon, melatonina, ramelteon, triazolam, etizolam, brotizolam e indiplon, o un derivado o una mezcla suya en cualquier combinacion.
ARP060103593A 2005-08-19 2006-08-17 Combinacion de un agente hipnotico y de r (+) - alfa-( 2,3- dimetoxi - fenil) -1- (2- (4-fluorofenil)etil]-4-piperidinmetanol y su aplicacion terapeutica AR055608A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70951005P 2005-08-19 2005-08-19

Publications (1)

Publication Number Publication Date
AR055608A1 true AR055608A1 (es) 2007-08-29

Family

ID=37772165

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103593A AR055608A1 (es) 2005-08-19 2006-08-17 Combinacion de un agente hipnotico y de r (+) - alfa-( 2,3- dimetoxi - fenil) -1- (2- (4-fluorofenil)etil]-4-piperidinmetanol y su aplicacion terapeutica

Country Status (14)

Country Link
US (1) US20080139615A1 (es)
EP (1) EP1937265A2 (es)
JP (1) JP2009504760A (es)
KR (1) KR20080034475A (es)
CN (1) CN101247810A (es)
AR (1) AR055608A1 (es)
AU (1) AU2006283702A1 (es)
BR (1) BRPI0615357A2 (es)
CA (1) CA2617975A1 (es)
IL (1) IL189557A0 (es)
MX (1) MX2008001705A (es)
RU (1) RU2008110477A (es)
TW (1) TW200815030A (es)
WO (1) WO2007024599A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2889811B1 (fr) * 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK42499A3 (en) * 1996-10-21 2000-05-16 Neurosearch As 1-phenyl-benzimidazole compounds and their use as gabaa receptor modulators
US6028083A (en) * 1997-07-25 2000-02-22 Hoechst Marion Roussel, Inc. Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol
US6277864B1 (en) * 1998-08-28 2001-08-21 Aventis Pharmaceuticals Inc. Use of R- +)-α-(2,3-dimethoxyphenyl-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol for the treatment of sleep disorders
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US20040258750A1 (en) * 1999-06-28 2004-12-23 Gerard Alaux Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
ES2277301T3 (es) * 2000-04-24 2007-07-01 Teva Pharmaceutical Industries Ltd. Solvato de hemitartrato de zolpidem.
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
TW200626137A (en) * 2004-12-13 2006-08-01 Takeda Pharmaceuticals Co Preventive or therapeutic agent for sleep disorder

Also Published As

Publication number Publication date
BRPI0615357A2 (pt) 2011-05-17
AU2006283702A1 (en) 2007-03-01
CN101247810A (zh) 2008-08-20
EP1937265A2 (en) 2008-07-02
RU2008110477A (ru) 2009-09-27
IL189557A0 (en) 2008-08-07
TW200815030A (en) 2008-04-01
US20080139615A1 (en) 2008-06-12
JP2009504760A (ja) 2009-02-05
MX2008001705A (es) 2008-04-07
WO2007024599A2 (en) 2007-03-01
KR20080034475A (ko) 2008-04-21
WO2007024599A3 (en) 2007-11-22
CA2617975A1 (en) 2007-03-01

Similar Documents

Publication Publication Date Title
NZ592425A (en) Isoindoline compounds for use in the treatment of cancer
PE20090714A1 (es) Imidazopiridazinas y pirrolo-pirimidinas sustituidas como inhibidores de cinasa de lipido
MY155255A (en) Spiro-oxindole compounds and their use as therapeutic agents
MX2012004848A (es) Compuestos heterociclicos triciclicos.
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
PE20120413A1 (es) ENANTIOMERO (S) DE 1'-{[5-(TRIFLUOROMETIL)FURAN-2-IL]METIL}ESPIRO[FURO[2,3-f][1,3]BENZODIOXOL-7,3'-INDOL]-2'(1'H)-ONA
CR8146A (es) Metodos para tratar canceres usando formas poliformicas de 3-(4-amino -1-oxo-1,3 dihidro-isoindol-2-il)- piperidina-2,6-dione
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
IS8503A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
UY29412A1 (es) Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos.
ATE549021T1 (de) Kombinationstherapien zur behandlung von morbus alzheimer mit dimebon und donepezil
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
MX2020012868A (es) Metodos y composiciones para trastornos del sue?o y otros trastornos.
CL2004000234A1 (es) Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
PE20080275A1 (es) Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
PA8493701A1 (es) Compuestos para tratar la obesidad
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
PE20060957A1 (es) Compuestos pirazolopiridinas su preparacion y composiciones farmaceuticas
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.
DE602005010744D1 (de) Piperazinylpyridinderivate als mittel gegen adipositas
CL2009000445A1 (es) Compuestos derivados de piperidina 1,4 heterociclo sustituidos, procedimiento para preparar estos compuestos, composicion farmaceutica que los comprende y su uso para la terapia del dolor y el tratamiento de enfermedades como alzheimer, esquizofrenia, ansiedad y depresion.
UY30577A1 (es) Derivados de éter diarilico y usos de los mismos

Legal Events

Date Code Title Description
FB Suspension of granting procedure